The Form 4 filing, an SEC report of insider stock activity, was filed on November 18, 2026. That was two days after the trades. The report lists Marion McCourt as executive vice president, commercial, at Regeneron Pharmaceuticals (REGN).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 13 |
| Shares Transacted | 566 |
| Price | $960.25 |
| Total Transaction Value | $543,504.06 |
| Insider | |
| Ticker Symbol | REGN |
| Company | REGENERON PHARMACEUTICALS, INC. |
| Insider Name | McCourt Marion |
| Insider Title | EVP Commercial |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 10,305 |
| Position Size Change | 5.21% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S. The report covers 13 sale transactions by one insider in one filing. All were dated November 16, 2026.
What was the average price of the transaction?
The average sale price was $960.25 per share across the 13 transactions. Prices for each separate sale were not provided.
How did this transaction affect the insider's holdings?
After selling 566 shares, Marion McCourt reported owning 10,305 shares. The shares sold made up 5.21% of the shares held before the sale.
What's the total transaction value?
The total sale value was $543,504.06 for all 566 shares. That amount covers the 13 reported sale transactions.
Are there any special circumstances around this transaction?
The filing information points to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. Footnote text and plan details were not provided, so it is unclear which of the 13 sales the plan reference covers. The plan’s start date and trading schedule are also unknown.
For research purposes only; not investment advice.